Replies to post #19507 on MindMaze Therapeutics Holding (RLFTF)

[trademax42]

Not sure what ticker you're talking about. If it's CYD*Y, the pps came down from $10 dollars to the current level below $5 dollars. And their phase II trials did not report stats significant results.

Phase 2 data released August 11, 2020 did not report primary endpoint data (TCSS at Day 14). Day 3 subgroup showed clinical improvement but not mentioned to be statistically significant. Secondary NEWS2 was met. No data on other secondary endpoints.

https://www.biopharmcatalyst.com/company/CYDY

The current MC is about $3 billion for CYD*Y. RLFTF's MC is only about one half of the above figure. This tells how undervalued this ticker is.


Quote from your post:

There is another company developing a monoclonal antibody to treat covid 19 that went up 10% today. The stock is up a a little less than 40% in the last two weeks.

$RLFTF

Disclaimer: Just my opinion, do your own dd.